Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Stock analysts at Leerink Partnrs dropped their Q1 2025 EPS estimates for Waters in a research note issued on Wednesday, ...

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...

Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a report issued on Wednesday, February 12th. Leerink Partnrs analyst ...

U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...

LUND, SE / ACCESS Newswire / February 19, 2025 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargia's management will participate in one-on-one meetin ...